ArticleAnimals : an open access journal from MDPI2025
Scopolamine-Induced Amnesia in Zebrafish: Behavioral Characterization and Pharmacological Reversal.
Article in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dioxopiperidinamide Derivative SKT-36 Alleviates scopolamine-induced Cognitive and Neurobehavioral Impairments in an In-vivo Zebrafish Model.Cell biochemistry and biophysics · 2026Article
- Postoperative delirium: from bundles to precision prevention.Anesthesia and pain medicine · 2026Review
- Therapeutic relevance of an EU-GMP certifiedFrontiers in pharmacology · 2026Article
- Melissa officinalis essential oil modulates oxidative balance, cholinergic activity, and cognitive performance in a scopolamine-induced zebrafish model: implications for neuroprotective strategies in cognitive disorders.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The main objective of this study was to assess whether donepezil or haloperidol, after a 10-day training period, could inhibit inhibitory avoidance and alter learned behavior. To assess memory impairment, zebrafish were trained in a light/dark tank over a 20-day period: 10 days without mechanical stimulation and 10 days with mechanical stimulation. Three behavioral parameters were recorded, i.e., latency to enter the dark compartment, time spent in the dark zone, and the number of entries into the dark area. Following the training phase, scopolamine was administered to induce amnesia. Donepezil and haloperidol were used as reference compounds for comparison. Subsequently, zebrafish were placed in a cylindrical tank, and spontaneous exploratory behavior was evaluated by measuring the amount of time spent in the upper region of the tank, an indicator of anxiety-related behavior. The behavioral data from the training phase were used to establish a baseline profile of zebrafish performance in the light/dark tank. Scopolamine administration significantly altered all of the measured behavioral parameters, including exploratory behavior in the cylindrical tank. Notably, donepezil or haloperidol prevented the memory-impairing effects of scopolamine, supporting the use of the light/dark tank paradigm to evaluate the efficacy of pharmacological agents in reversing scopolamine-induced amnesia in zebrafish.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.